The 2026 Low-Grade Serous Ovarian Cancer (LGSOC) Consensus Conference is a landmark virtual event bringing together leading experts to align on the latest evidence and best practices for diagnosing, treating, and managing this rare and underresearched ovarian cancer subtype.

Taking place virtually on Friday, April 17, 2026 from 8:00 AM to 2:00 PM ET, this focused one-day conference is designed to build consensus across the most pressing clinical and scientific questions in LGSOC care — from upfront treatment decisions to what happens when disease comes back.

The 2026 LGSOC Consensus Conference

Low-grade serous ovarian cancer is diagnosed in women significantly younger than the typical ovarian cancer patient — often in their 30s and 40s — and it behaves differently than the high-grade disease that most research has historically focused on. It’s slower growing, often resistant to standard chemotherapy, and prone to recurrence. Yet dedicated, expert-level clinical consensus on how to manage it has remained elusive.

This conference aims to change that.

By convening specialists across pathology, oncology, radiology, regulatory science, and patient advocacy, the 2026 LGSOC Consensus Conference will work toward shared clinical guidance that can meaningfully improve outcomes for patients living with this disease

Why This Conference Matters

LGSOC represents one of the most underserved areas in gynecologic oncology. There are currently no FDA-approved therapies specifically indicated for low-grade serous ovarian cancer: a gap that leaves patients, oncologists, and researchers working without a clear roadmap.

Events like this consensus conference are a critical step toward changing that reality. When experts from across specialties come together to align on what the evidence shows (and where gaps remain), it creates the foundation for better clinical guidelines, stronger research priorities, and ultimately, better outcomes for patients.

At Not These Ovaries, we believe urgency is not optional when it comes to LGSOC. That’s why we’re committed to supporting the scientific conversations, research, and trials that will move the needle — now, not years from now.